Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
posted on
Sep 25, 2024 06:09PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
OK, then don't settle down. No skin of my back!
Koo